Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors.

Ahsan A, Ramanand SG, Whitehead C, Hiniker SM, Rehemtulla A, Pratt WB, Jolly S, Gouveia C, Truong K, Van Waes C, Ray D, Lawrence TS, Nyati MK.

Neoplasia. 2012 Aug;14(8):670-7.

3.

Pnck induces ligand-independent EGFR degradation by probable perturbation of the Hsp90 chaperone complex.

Deb TB, Zuo AH, Wang Y, Barndt RJ, Cheema AK, Sengupta S, Coticchia CM, Johnson MD.

Am J Physiol Cell Physiol. 2011 May;300(5):C1139-54. doi: 10.1152/ajpcell.00167.2010. Epub 2011 Feb 16.

4.

Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification.

Jang WJ, Jung SK, Kang JS, Jeong JW, Bae MK, Joo SH, Park GH, Kundu JK, Hong YS, Jeong CH.

Cancer Sci. 2014 Oct;105(10):1245-53. doi: 10.1111/cas.12497. Epub 2014 Sep 25.

5.

Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.

Lang SA, Klein D, Moser C, Gaumann A, Glockzin G, Dahlke MH, Dietmaier W, Bolder U, Schlitt HJ, Geissler EK, Stoeltzing O.

Mol Cancer Ther. 2007 Mar;6(3):1123-32.

6.

The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.

Smith DL, Acquaviva J, Sequeira M, Jimenez JP, Zhang C, Sang J, Bates RC, Proia DA.

Target Oncol. 2015 Jun;10(2):235-45. doi: 10.1007/s11523-014-0329-6. Epub 2014 Aug 1.

7.

A role of Rab7 in stabilizing EGFR-Her2 and in sustaining Akt survival signal.

Wang T, Zhang M, Ma Z, Guo K, Tergaonkar V, Zeng Q, Hong W.

J Cell Physiol. 2012 Jun;227(6):2788-97. doi: 10.1002/jcp.23023.

PMID:
21928319
8.

Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis.

Koizumi H, Yamada T, Takeuchi S, Nakagawa T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Yano S.

J Thorac Oncol. 2012 Jul;7(7):1078-85. doi: 10.1097/JTO.0b013e3182519a2c.

9.

Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.

Ono N, Yamazaki T, Tsukaguchi T, Fujii T, Sakata K, Suda A, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y.

Cancer Sci. 2013 Oct;104(10):1346-52. doi: 10.1111/cas.12237. Epub 2013 Aug 20.

10.

HSP90 inhibitors induce desensitization of EGF receptor via p38 MAPK-mediated phosphorylation at Ser1046/1047 in human pancreatic cancer cells.

Adachi S, Yasuda I, Nakashima M, Yamauchi T, Yamauchi J, Natsume H, Moriwaki H, Kozawa O.

Oncol Rep. 2010 Jun;23(6):1709-14.

PMID:
20428829
11.

Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.

Pedersen NM, Breen K, Rødland MS, Haslekås C, Stang E, Madshus IH.

Mol Cancer Res. 2009 Feb;7(2):275-84. doi: 10.1158/1541-7786.MCR-07-2183. Epub 2009 Feb 10.

12.

A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation.

Chan KC, Ting CM, Chan PS, Lo MC, Lo KW, Curry JE, Smyth T, Lee AW, Ng WT, Tsao GS, Wong RN, Lung ML, Mak NK.

Mol Cancer. 2013 Oct 24;12(1):128. doi: 10.1186/1476-4598-12-128.

13.

Destabilization of the epidermal growth factor receptor (EGFR) by a peptide that inhibits EGFR binding to heat shock protein 90 and receptor dimerization.

Ahsan A, Ray D, Ramanand SG, Hegde A, Whitehead C, Rehemtulla A, Morishima Y, Pratt WB, Osawa Y, Lawrence TS, Nyati MK.

J Biol Chem. 2013 Sep 13;288(37):26879-86. doi: 10.1074/jbc.M113.492280. Epub 2013 Jul 29.

14.

Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.

Ono N, Yamazaki T, Nakanishi Y, Fujii T, Sakata K, Tachibana Y, Suda A, Hada K, Miura T, Sato S, Saitoh R, Nakano K, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y.

Cancer Sci. 2012 Feb;103(2):342-9. doi: 10.1111/j.1349-7006.2011.02144.x. Epub 2011 Dec 13.

15.

Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation.

Jiao Y, Ou W, Meng F, Zhou H, Wang A.

Mol Cancer. 2011 Sep 30;10:125. doi: 10.1186/1476-4598-10-125.

16.

Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.

Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L, Li D, Carretero J, Li YC, Sinha P, Carey CD, Borgman CL, Jimenez JP, Meyerson M, Ying W, Barsoum J, Wong KK, Shapiro GI.

Clin Cancer Res. 2012 Sep 15;18(18):4973-85. doi: 10.1158/1078-0432.CCR-11-2967. Epub 2012 Jul 17.

17.

Molecular imaging of EGFR and CD44v6 for prediction and response monitoring of HSP90 inhibition in an in vivo squamous cell carcinoma model.

Spiegelberg D, Mortensen AC, Selvaraju RK, Eriksson O, Stenerlöw B, Nestor M.

Eur J Nucl Med Mol Imaging. 2016 May;43(5):974-82. doi: 10.1007/s00259-015-3260-x. Epub 2015 Dec 1.

18.

Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.

Sawai A, Chandarlapaty S, Greulich H, Gonen M, Ye Q, Arteaga CL, Sellers W, Rosen N, Solit DB.

Cancer Res. 2008 Jan 15;68(2):589-96. doi: 10.1158/0008-5472.CAN-07-1570.

19.

Cytosolic PKM2 stabilizes mutant EGFR protein expression through regulating HSP90-EGFR association.

Yang YC, Cheng TY, Huang SM, Su CY, Yang PW, Lee JM, Chen CK, Hsiao M, Hua KT, Kuo ML.

Oncogene. 2016 Jun 30;35(26):3387-98. doi: 10.1038/onc.2015.397. Epub 2015 Oct 26. Erratum in: Oncogene. 2017 Jul 20;36(29):4234.

PMID:
26500058
20.

The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.

Smyth T, Van Looy T, Curry JE, Rodriguez-Lopez AM, Wozniak A, Zhu M, Donsky R, Morgan JG, Mayeda M, Fletcher JA, Schöffski P, Lyons J, Thompson NT, Wallis NG.

Mol Cancer Ther. 2012 Aug;11(8):1799-808. doi: 10.1158/1535-7163.MCT-11-1046. Epub 2012 Jun 19.

Supplemental Content

Support Center